Basis: Current FMP quote-based enterprise value / four-quarter operating income plus matched D&A. Source: stored company filings and market data; unavailable inputs remain N/A.
The EV/EBITDA ratio is N/A as of 2026-10-06T17:03:26.915Z.
Calculation as of: 2026-10-06T17:03:26.915Z.
Quote observation: 2026-10-06T17:00:53.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 9cbfdb9b702203632c67f1d3ce56f9042d1c779579fe07ac28526a5c99bc9a0a
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EV/EBITDA RATIO
N/A
Market Cap
$446.11M
EV/EBITDA Ratio
N/A
TTM Avg
0.21x
3Y Avg
0.21x
5Y Avg
0.21x
Market Cap
$440.73M
EV/EBITDA Ratio
0.44x
TTM Avg
1.11x
3Y Avg
1.11x
5Y Avg
1.11x
Market Cap
$448.71M
EV/EBITDA Ratio
N/A
TTM Avg
81.39x
3Y Avg
32.05x
5Y Avg
24.98x
Market Cap
$435.48M
EV/EBITDA Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$429.49M
EV/EBITDA Ratio
N/A
TTM Avg
74.72x
3Y Avg
37.71x
5Y Avg
26.88x
Market Cap
$423.53M
EV/EBITDA Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | EV/EBITDA RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| NeuroPace, Inc. (NPCE) | $444.41M | N/A | N/A | N/A | N/A |
| Ovid Therapeutics Inc. (OVID)vs › | $446.11M | N/A | 0.21x | 0.21x | 0.21x |
| Capricor Therapeutics, Inc. (CAPR)vs › | $440.73M | 0.44x | 1.11x | 1.11x | 1.11x |
| DiaMedica Therapeutics Inc. (DMAC)vs › | $448.71M | N/A | 81.39x | 32.05x | 24.98x |
| Assembly Biosciences, Inc. (ASMB)vs › | $435.48M | N/A | N/A | N/A | N/A |
| Editas Medicine, Inc. (EDIT)vs › | $435.06M | N/A | N/A | N/A | N/A |
| NeoGenomics, Inc. (NEO)vs › | $429.49M | N/A | 74.72x | 37.71x | 26.88x |
| NRC Health (NRC)vs › | $459.39M | 23.37x | 16.39x | 15.03x | 16.69x |
| ARS Pharmaceuticals, Inc. (SPRY)vs › | $423.53M | N/A | N/A | N/A | N/A |
| Sight Sciences, Inc. (SGHT)vs › | $468.74M | N/A | N/A | N/A | N/A |
EV/EBITDA = Enterprise Value / EBITDA (TTM)
Enterprise value to EBITDA is a capital-structure-neutral valuation multiple, useful for comparing companies with different debt levels and tax rates.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
